Preparation and immunogenicity of a Pichia pastoris-derived hepatitis B vaccine containing preS1, preS2 and S epitopes.
- Author:
Chang-Yao TAN
1
;
Jin YUAN
;
Ou JIN
;
Li-Ming JIANG
;
Bo HU
Author Information
1. Laboratory of Biotechnology, Chengdu Institute of Biological Products, Chengdu 610023, China. changyao_tan@hotmail.com
- Publication Type:Journal Article
- MeSH:
Animals;
Epitopes;
immunology;
Female;
Hepatitis B Surface Antigens;
immunology;
Hepatitis B Vaccines;
biosynthesis;
immunology;
Mice;
Pichia;
genetics;
metabolism;
Protein Engineering;
Protein Precursors;
immunology;
Recombinant Proteins;
biosynthesis;
genetics;
immunology;
Viral Envelope Proteins;
immunology
- From:
Chinese Journal of Biotechnology
2007;23(4):700-703
- CountryChina
- Language:Chinese
-
Abstract:
The preparation process and immunogenicity of a novel hepatitis B vaccine containing preS1, preS2 and S epitopes were investigated in this study. A Pichia pastoris stain GS115-SS1S2 harbouring two chimeric HBsAg gene constructs, SS1 and SS2 was cultivated by high-density fermentation. 300-600 mg/L of the expression level was achieved through 48-72 h methanol induction. SSIS2 antigen was extracted and purified by silica adsorption, HIC and SEC to 99% purity from the harvested cells. 82 mg purified antigen could be achieved from one liter of fermentation culture. The immunogenicity of the purified antigen was evaluated in NIH mice. Three groups of female NIH mice, 14-16 g in weight, were injected once intraperitoneally with 2.5, 0.625, 0.156 microg of each of the two vaccines: SS1S2 or a commercially available S vaccine. Part of the mice were bled in 30 days after injection to compare the ED50 of the two vaccines. For the SSIS2 vaccine, the ED50 is 0.46, 0.29 and 0.84 microg respectively for the preS1, preS2 and S antigens. For the S vaccine, the ED50 is 0.99 microg for the S antigen. Another part of the mice were bleed in 7 or 14 days to detect preS1, preS2 and S antibodies. Higher ratios of mice were seroconverted for preS1 and preS2 antibodies as compared to the S antibody in these two time points. These results suggest that the SS1S2 vaccine may be more immunogenic than the conventional S vaccines.
